

# DR. sc. hum. KERSTIN ANNE EITZ

Klinik für RadioOnkologie und Strahlentherapie  
 Technische Universität München (TUM)  
 Klinikum rechts der Isar  
 Ismaninger Str. 22  
 81675 München  
 mail: kerstin.eitz@tum.de

\* 17. Februar 1984 in Schwetzingen, geb. Kessel

## Schulbildung

---

Mär 2003 Abitur an der Privaten Maria-Ward-Schule, Landau in der Pfalz

## Hochschulbildung

---

Apr 2003 – Aug 2008 Studium Medizinische Informatik an der Ruprecht-Karls-Universität Heidelberg / Hochschule Heilbronn

Jun 2006 Teilnahme an der IPHIE Master Class in Minneapolis, USA

Okt 2007 – Mai 2008 Diplomand am Surgical Planning Laboratory, Brigham and Women's Hospital / Harvard Medical School, Boston, USA, Thema: *Inspection and Editing Tool for Diffusion Weighted MRI* (Note: sehr gut)

31. Jul 2008 Diplomprüfung (Diplom-Informatikerin der Medizin) (Note: gut)

## Beruflicher Werdegang

---

Sep 2008 – Aug 2010 Wissenschaftliche Mitarbeiterin an der Hochschule Heilbronn im Studiengang Medizinische Informatik

Jan 2010 – Mär 2014 Akademische Mitarbeiterin am Heidelberger Ionenstrahl-Therapiezentrum (HIT) der Abteilung für RadioOnkologie und Strahlentherapie des Universitätsklinikums Heidelberg, Prof. Dr. Dr. Jürgen Debus

24. Mär 2014 Dissertation an der Medizinischen Fakultät Heidelberg der Ruprecht-Karls-Universität zur Erlangung des Doctor scientiarum humanarum (Dr.sc.hum.), Prof. Dr. Stephanie E. Combs, Thema: *Development of an integrated electronic data collection and analysis system in radiation oncology: workflow characterisation, system design, implementation and verification using the clinical example of pancreatic cancer* (Note: magna cum laude)

seit Apr 2014 Leiterin der Arbeitsgruppe für Medizinische Informatik in der RadioOnkologie an der Klinik und Poliklinik für RadioOnkologie und Strahlentherapie der Technische Universität München (TUM), Klinikum rechts der Isar

seit Feb 2017 Wissenschaftliche Koordinatorin des Zentrums für Stereotaxie und personalisierte Hochpräzisionsstrahlentherapie (STEREOTAKTUM)

Aug 2017 - Sep 2017 Forschungsaufenthalt am BC Cancer Center, Dep. Radiation Oncology, University of British Columbia, Kelowna, Kanada (ERASMUS+ grant)

## Stipendien, Preise und Zertifikate

Sep 2007	Stipendium des Lions Club Heilbronn / Franken
Aug 2017	ERASMUS+ Staff Mobility Grant for Training
Juni 2018	DEGRO Innovationspreis 2018
Okt 2018	Zertifikat "Leadership Academy für ProfessorInnen und leitende WissenschaftsmanagerInnen" der TUM School of Management

## Lehrtätigkeit

Doktorandenseminar in der Radioonkologie	5 Unterrichtseinheiten à 60 min pro Semester
Vorlesung "Research data management" im Masterstudiengang Radiation Biology	5 Unterrichtseinheiten à 90 min im Wintersemester
Vorlesung "Klinische Studien" im Wahlpflichtfach „RadioOnkologie integrativ“	1 Unterrichtseinheiten à 90 min pro Semester

## Betreute Dissertationen / Abschlussarbeiten

### Dr. med.

Rebecca Asadpour	Verwendung von Akupunktur unter Strahlentherapie: Bringt Verum-Akupunktur einen Benefit gegenüber einer Sham-Akupunktur	abgeschlossen, publiziert
Geraldine Bihoi	Untersuchung der Strahlendosis an der Cochlea bei Patienten mit Akustikusneurinom nach Radiotherapie, sowie die Auswirkung auf die Hörminderung	abgeschlossen
Andrea Deichl	Auswertung des Langzeitverlaufs nach stereotaktischer Bestrahlung bei Hirnmetastasen	abgeschlossen, publiziert
Hanna Fischer	Der Einfluss der [68Ga]-DOTANOC-PET-Bildgebung bei der Strahlentherapie-planung von Patienten mit Meningeomen hinsichtlich Toxizität und Rezidivhäufigkeit	abgeschlossen publiziert
Frederik Fuchs	Adaptive Radiotherapie bei Patienten mit Prostatakarzinom: Konzept zur individualisierte Radiotherapie (iRT)	abgeschlossen publiziert
Rebekka Grosser	Long term follow-up and patient reported outcome (PRO) of patients treated with body stereotactic radiotherapy	abgeschlossen, publiziert
Josefine Hesse	Multimodale Rezidivmusteranalyse und Evaluation der Toxizität sowie Überleben nach Strahlentherapie bei Patienten mit höhergradigen Gliomen	laufend, publiziert
Christoph Knie	Neoadjuvante Radiotherapie von Weichteilsarkomen der Extremitäten	abgeschlossen, publiziert
Sabrina Lettner	Komplementärmedizinische Behandlung als Teil der radioonkologischen Therapie – Fragebogen zur Evaluation der Akzeptanz sowie des Umgangs mit dem Therapieangebot in einer großen deutschen Abteilung für RadioOnkologie	abgeschlossen publiziert
Teresa Neff	Erfassung und Analyse der Langzeitergebnisse nach Neutronentherapie	abgeschlossen
Elena Salfelder	Outcome und Toxizität nach Tomotherapie bei kindlichen Tumoren	laufend, publiziert

Hannah Scholz	Comparison of current prognostic scores in glioblastoma	laufend
Anna Schmidt	Retrospektive Analyse der stereotaktischen Radiotherapie am Klinikum rechts der Isar	abgeschlossen
Theresa Voglhuber	Patterns-of-Care und Outcome-Analyse der Radiotherapie von abdominalen Metastasen	laufend, publiziert

**Dr. med. dent.**

Chaline May	Relevanz der MRT-Bildgebung während der Strahlentherapie in Bezug auf Tumorgeometrie und Veränderungen von Risikoorganen bei Patienten mit Karzinomen im HNO-Bereich	abgeschlossen
-------------	--	---------------

**B. Sc.**

Anna Alles	Entwicklung und Validierung einer mobilen Applikation (App) für iOS basierend auf Swift 2.0 zur therapiebegleitenden Erfassung der Lebensqualität bei onkologischen Patienten	abgeschlossen, publiziert Note 1.3
------------	---	--

## Publikationen

**Original paper, Pubmed listed**

- Voglhuber T, **Kessel KA**, Oechsner M, Vogel MME, Gschwend JE, Combs SE: 'Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases', BMC Cancer, 2020, 20, (1), pp. 536
- Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao D, Serizawa T, Yomo S, Aiyama H, Higuchi Y, Shuto T, Akabane A, Sato Y, Niranjana A, Faramand AM, Lunsford LD, McNerney J, Tuanquin LC, Zacharia BE, Chiang V, Singh C, Yu JB, Braunstein S, Mathieu D, Touchette CJ, Lee CC, Yang HC, Aizer AA, Cagney DN, Chan MD, Kondziolka D, Bernstein K, Silverman JS, Grills IS, Siddiqui ZA, Yuan JC, Sheehan JP, Cordeiro D, Nosaki K, Seto T, Deibert CP, Verma V, Day S, Halasz LM, Warnick RE, Trifiletti DM, Palmer JD, Attia A, Li B, Cifarelli CP, Brown PD, Vargo JA, Combs S, **Kessel KA**, Rieken S, Patel S, Guckenberger M, Andratschke N, Kavanagh BD, Robin TP: 'Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study', JAMA Oncol, 2020
- Kessel KA**, Grosser RCE, Kraus KM, Hoffmann H, Oechsner M, Combs SE: 'Stereotactic body radiotherapy (SBRT) in patients with lung metastases - prognostic factors and long-term survival using patient self-reported outcome (PRO)', BMC Cancer, 2020, 20, (1), pp. 442
- Straube C, **Kessel KA**, Antoni S, Gempt J, Meyer B, Schlegel J, Schmidt-Graf F, Combs SE: 'A balanced score to predict survival of elderly patients newly diagnosed with glioblastoma', Radiat Oncol, 2020, 15, (1), pp. 97
- Kessel KA**, Weber W, Yakushev I, Fischer H, Voglhuber T, Diehl C, Straube C, Zimmer C, Wiestler B, Gempt J, Meyer B, Combs SE: 'Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome', Eur J Nucl Med Mol Imaging, 2020, 47, (6), pp. 1391-1399
- Borm KJ, **Kessel KA**, Devecka M, Muench S, Straube C, Schiller K, Schuttrumpf L, Dapper H, Woller B, Pigorsch S, Combs SE: 'Variability in lymph node irradiation in patients with breast cancer-results from a multi-center survey in German-speaking countries', Strahlenther Onkol, 2020, 196, (1), pp. 15-22
- Kessel KA**, Diehl CD, Oechsner M, Meyer B, Gempt J, Zimmer C, Schmidt-Graf F, Combs SE: Patient-Reported Outcome (PRO) as an Addition to Long-Term Results after High-Precision Stereotactic Radiotherapy in Patients with Secreting and Non-Secreting Pituitary Adenomas: A Retrospective Cohort Study up to 17-Years Follow-Up. Cancers 2019, 11(12).
- Vogel MME, **Kessel KA**, Schiller K, Devecka M, Gschwend JE, Weichert W, Wilkens JJ, Combs SE: Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy. Radiat Oncol 2019, 14(1):198.
- Scharl S, Kirstein A, **Kessel KA**, Duma MN, Oechsner M, Straube C, Combs SE: Cavity volume changes after

- surgery of a brain metastasis-consequences for stereotactic radiation therapy. *Strahlenther Onkol* 2019, 195(3):207-217.
10. Vogel MME, **Kessel KA**, Gschwend JE, Weichert W, Wilkens JJ, Combs SE: Early and late toxicity profiles of patients receiving immediate postoperative radiotherapy versus salvage radiotherapy for prostate cancer after prostatectomy. *Strahlenther Onkol* 2019, 195(2):131-144.
  11. Lämmer F, Delbridge C, Würstle S, Neff F, Meyer B, Schlegel J, **Kessel KA**, Schmid TE, Schilling D, Combs SE. Cytosolic Hsp70 as a biomarker to predict clinical outcome in patients with glioblastoma. *PLoS One*. 2019 Aug 20;14(8):e0221502.
  12. Scharl S, Kirstein A, **Kessel KA**, Diehl C, Oechsner M, Straube C, Meyer B, Zimmer C, Combs SE. Stereotactic irradiation of the resection cavity after surgical resection of brain metastases - when is the right timing? *Acta Oncol*. 2019, 58(12):1714-1719.
  13. Straube C, **Kessel KA**, Zimmer C, Schmidt-Graf F, Schlegel J, Gempt J, Meyer B, Combs SE. A Second Course of Radiotherapy in Patients with Recurrent Malignant Gliomas: Clinical Data on Re-irradiation, Prognostic Factors, and Usefulness of Digital Biomarkers. *Curr Treat Options Oncol*. 2019 19;20(9):71.
  14. Fuchs F, Habl G, Devecka M, Kampfer S, Combs SE, **Kessel KA**: Interfraction variation and dosimetric changes during image-guided radiation therapy in prostate cancer patients. *Radiat Oncol J* 2019, 37:127-133.
  15. Peeken JC, Knie C, **Kessel KA**, Habermehl D, Kampfer S, Dapper H, Devecka M, Eisenhart-Rothe von R, Specht K, Weichert W, Wörtler K, Knebel C, Wilkens JJ, Combs SE. Neoadjuvant image-guided helical intensity modulated radiotherapy of extremity sarcomas - a single center experience. *Radiat Oncol* 2019; 14: 2.
  16. Peeken JC, Goldberg T, Pyka T, Bernhofer M, Wiestler B, **Kessel KA**, Tafti PD, Nüsslin F, Braun AE, Zimmer C, Rost B, Combs SE. Combining multimodal imaging and treatment features improves machine learning-based prognostic assessment in patients with glioblastoma multiforme. *Cancer Med* 2019, 8(1):128-136.
  17. Wank M, Schilling D, Schmid TE, Meyer B, Gempt J, Barz M, Schlegel J, Liesche F, **Kessel KA**, Wiestler B, Bette S, Zimmer C, Combs SE. Human Glioma Migration and Infiltration Properties as a Target for Personalized Radiation Medicine. *Cancers* 2018; 10: 456.
  18. **Kessel KA**, Vogel MME, Kessel C, Bier H, Biedermann T, Friess H, Herschbach P, Eisenhart-Rothe von R, Meyer B, Kiechle M, Keller U, Peschel C, Bassermann F, Schmid R, Schwaiger M, Combs SE. Cancer clinical trials – Survey evaluating patient participation and acceptance in a university-based Comprehensive Cancer Center (CCC). *Clinical and Translational Radiation Oncology* 2018; 13: 44-9.
  19. **Kessel KA**, Klein E, Hack CC, Combs SE. Complementary medicine in radiation oncology : German health care professionals' current qualifications and therapeutic methods. *Strahlenther Onkol* 2018; 194: 904-10.
  20. Straube C, **Kessel KA**, Schmidt-Graf F, Krieg SM, Meyer B, Gempt J, Combs SE. A trend towards a more intense adjuvant treatment of low-grade-gliomas in tertiary centers in Germany after RTOG 9802 - results from a multi-center survey. *BMC Cancer* 2018; 18: 907.
  21. Combs SE, Niyazi M, Adeberg S, Bougatf N, Kaul D, Fleischmann DF, Grün A, Fokas E, Rödel CM, Eckert F, Paulsen F, Oehlke O, Grosu A-L, Seidlitz A, Lattermann A, Krause M, Baumann M, Guberina M, Stuschke M, Budach V, Belka C, Debus J, **Kessel KA**. Re-irradiation of recurrent gliomas: Pooled analysis and validation of an established prognostic score - Report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK). *Cancer Med* 2018; 18: 549.
  22. Peeken JC, Hesse J, Haller B, Kessel KA, Nüsslin F, Combs SE. Semantic imaging features predict disease progression and survival in glioblastoma multiforme patients. *Strahlenther Onkol* 2018; 194: 580-90.
  23. Shafie El RA, Czech M, **Kessel KA**, Habermehl D, Weber D, Rieken S, Bougatf N, Jäkel O, Debus J, Combs SE. Evaluation of particle radiotherapy for the re-irradiation of recurrent intracranial meningioma. *Radiat Oncol* 2018; 13: 86.
  24. Shafie El RA, Czech M, **Kessel KA**, Habermehl D, Weber D, Rieken S, Bougatf N, Jäkel O, Debus J, Combs SE. Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning. *Radiat Oncol* 2018; 13: 54.
  25. Peeken JC, Goldberg T, Knie C, Komboz B, Bernhofer M, Pasa F, **Kessel KA**, Tafti PD, Rost B, Nüsslin F, Braun AE, Combs SE. Treatment-related features improve machine learning prediction of prognosis in soft tissue sarcoma patients. *Strahlenther Onkol* 2018; 141: 105.

26. **Kessel KA**, Vogel MM, Alles A, Dobiasch S, Fischer H, Combs SE. Mobile App Delivery of the EORTC QLQ-C30 Questionnaire to Assess Health-Related Quality of Life in Oncological Patients: Usability Study. *JMIR Mhealth Uhealth* 2018; 6: e45.
27. Combs SE, **Kessel KA**, Hesse J, Straube C, Zimmer C, Schmidt-Graf F, Schlegel J, Gempt J, Meyer B. Moving Second Courses of Radiotherapy Forward: Early Re-Irradiation After Surgical Resection for Recurrent Gliomas Improves Efficacy With Excellent Tolerability. *Neurosurgery* 2018; 158: 545.
28. Niyazi M, Adeberg S, Kaul D, Boulesteix A-L, Bougatf N, Fleischmann DF, Grün A, Krämer A, Rödel CM, Eckert F, Paulsen F, **Kessel KA**, Combs SE, Oehlke O, Grosu A-L, Seidlitz A, Lattermann A, Krause M, Baumann M, Guberina M, Stuschke M, Budach V, Belka C, Debus J. Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis. *Radiother Oncol* 2018; 127: 121–7.
29. Asadpour R, **Kessel KA**, Bruckner T, Sertel S, Combs SE. Randomized study exploring the combination of radiotherapy with two types of acupuncture treatment (ROSETTA): study protocol for a randomized controlled trial. *Trials* 2017; 18: 398.
30. **Kessel KA**, Hesse J, Straube C, Zimmer C, Schmidt-Graf F, Schlegel J, Meyer B, Combs SE. Modification and optimization of an established prognostic score after re-irradiation of recurrent glioma. *PLoS One* 2017; 12: e0180457-10.
31. **Kessel KA**, Fischer H, Oechsner M, Zimmer C, Meyer B, Combs SE. High-precision radiotherapy for meningiomas : Long-term results and patient-reported outcome (PRO). *Strahlenther Onkol* 2017; 29: 197.
32. **Kessel KA**, Vogel MM, Kessel C, Bier H, Biedermann T, Friess H, Herschbach P, Eisenhart-Rothe von R, Meyer B, Kiechle M, Keller U, Peschel C, Schmid RM, Combs SE. Mobile Health in Oncology: A Patient Survey About App-Assisted Cancer Care. *JMIR Mhealth Uhealth* 2017; 5: e81–7.
33. Habl G, Straube C, Schiller K, Duma MN, Oechsner M, **Kessel KA**, Eiber M, Schwaiger M, Kübler H, Gschwend JE, Combs SE. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). *BMC Cancer* 2017; 17: 361.
34. Vogel MME, Combs SE, **Kessel KA**. mHealth and Application Technology Supporting Clinical Trials: Today's Limitations and Future Perspective of smartRCTs. *Front Oncol* 2017; 7: 262–6.
35. Lettner S, **Kessel KA**, Combs SE. Complementary and alternative medicine in radiation oncology. *Strahlenther Onkol* 2017; 16: 655.
36. **Kessel KA**, Hesse J, Straube C, Zimmer C, Schmidt-Graf F, Schlegel J, Meyer B, Combs SE. Validation of an established prognostic score after re-irradiation of recurrent glioma. *Acta Oncologica* 2017; 56: 422–6.
37. **Kessel KA**, Vogel MM, Schmidt-Graf F, Combs SE. Mobile Apps in Oncology: A Survey on Health Care Professionals' Attitude Toward Telemedicine, mHealth, and Oncological Apps. *J Med Internet Res* 2016; 18:e312–9.
38. **Kessel KA**, Lettner S, Kessel C, Bier H, Biedermann T, Friess H, Herrschbach P, Gschwend J E, Meyer B, Peschel C, Schmid R, Schwaiger M, Wolff K-D and Combs SE. Use of Complementary and Alternative Medicine (CAM) as part of the oncological treatment: Survey about patients' attitude towards CAM in a university-based Oncology Center in Germany. *PLoS One*. 2016; 11:e0165801.
39. **Kessel KA**, Fischer H, Vogel M, Oechsner M, Duma M N, Bier H, Meyer B and Combs SE. Fractionated vs. single fraction stereotactic radiotherapy in patients with vestibular schwannoma: Hearing preservation and patients' self-reported outcome based on an established questionnaire. *Strahlenther Onkol* 2017; 193: 192–9.
40. Specht HM, **Kessel KA**, Oechsner M, Meyer B, Zimmer C, Combs SE: HFSRT of the resection cavity in patients with brain metastases. *Strahlenther Onkol*. 2016;192:368–76.
41. Habl G, Uhl M, Katayama S, **Kessel KA**, Hatiboglu G, Hadaschik B, Edler L, Tichy D, Ellerbrock M, Haberer T, Wolf MB, Schlemmer H-P, Debus J, Herfarth K: Acute toxicity and quality of life in patients with prostate cancer treated with protons or carbon ions in a prospective randomized phase II study – the IPI trial. *Int. J. Radiat. Oncol. Biol. Phys.* 2016;95:435–43.
42. **Kessel KA**, Combs SE: Data management, documentation and analysis systems in radiation oncology: a multi-institutional survey. *Radiat Oncol* 2015, 10:230.
43. Habl G, Katayama S, Uhl M, **Kessel KA**, Edler L, Debus J, Herfarth K, Sterzing F: Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate - first results of

- the PLATIN 1 trial. *BMC Cancer* 2015, 15:868.
44. Rieber JG, **Kessel KA**, Witt O, Behnisch W, Kulozik AE, Debus J, Combs SE: Treatment tolerance of particle therapy in pediatric patients. *Acta Oncologica* 2015, 54:1049–1055.
  45. **Kessel KA**, Jäger A, Habermehl D, Ruppell J, Bendl R, Debus J, Combs SE: Changes in Gross Tumor Volume and Organ Motion Analysis During Neoadjuvant Radiochemotherapy in Patients With Locally Advanced Pancreatic Cancer Using an In-House Analysis System. *Technol Cancer Res Treat* 2015, 15:348–354.
  46. Katayama S, Striecker T, **Kessel KA**, Sterzing F, Habl G, Edler L, Debus J, Herfarth K: Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial. *Int J Radiat Oncol Biol Phys* 2014, 90:926–933.
  47. Combs SE, Habermehl D, **Kessel KA**, Bergmann F, Werner J, Naumann P, Jäger D, Büchler MW, Debus J: Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer. *Ann Surg Oncol* 2014, 21:2801–2807.
  48. Koerber SA, Slynko A, Haefner MF, Krug D, Schoneweg C, **Kessel KA**, Kopp-Schneider A, Herfarth K, Debus J, Sterzing F: Efficacy and toxicity of chemoradiation in patients with anal cancer - a retrospective analysis. *Radiat Oncol* 2014, 9:113.
  49. **Kessel KA**, Bohn C, Engelmann U, Oetzel D, Bougatf N, Bendl R, Debus J, Combs SE: Five-year experience with setup and implementation of an integrated database system for clinical documentation and research. *Comput Methods Programs Biomed* 2014, 114:206–217.
  50. Katayama S, Habl G, **Kessel KA**, Edler L, Debus J, Herfarth K, Sterzing F: Helical intensity-modulated Radiotherapy of the Pelvic Lymph Nodes with Integrated Boost to the Prostate Bed - Initial Results of the PLATIN 3 Trial. *BMC Cancer* 2014, 14:20.
  51. Combs SE, Salehi-Allameh B, Habermehl D, **Kessel KA**, Welzel T, Debus J: Clinical response and tumor control based on long-term follow-up and patient-reported outcomes in patients with chemodectomas of the skull base and head and neck region treated with highly conformal radiation therapy. *Head Neck* 2014, 36:22–27.
  52. Combs SE, Habermehl D, **Kessel KA**, Bergmann F, Werner J, Brecht IC, Schirmacher P, Jäger D, Büchler MW, Debus J: Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer : Outcome analysis and comparison with a 3D-treated patient cohort. *Strahlenther Onkol* 2013, 189:738–744.
  53. Combs SE, **Kessel KA**, Habermehl D, Haberer T, Jäkel O, Debus J: Proton and carbon ion radiotherapy for primary brain tumors and tumors of the skull base. *Acta Oncol* 2013, 52:1504–1509.
  54. **Kessel KA**, Habermehl D, Jäger A, Floca RO, Zhang L, Bendl R, Debus J, Combs SE: Development and validation of automatic tools for interactive recurrence analysis in radiation therapy: optimization of treatment algorithms for locally advanced pancreatic cancer. *Radiat Oncol* 2013, 8:138.
  55. Combs SE, Welzel T, Habermehl D, Rieken S, Dittmar J-O, **Kessel KA**, Jäkel O, Haberkorn U, Debus J: Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and 68Ga-DOTATOC-PET. *Acta Oncol* 2013, 52:514–520.
  56. Combs SE, Welzel T, **Kessel KA**, Habermehl D, Rieken S, Schramm O, Debus J: Hearing preservation after radiotherapy for vestibular schwannomas is comparable to hearing deterioration in healthy adults and is accompanied by local tumor control and a highly preserved quality of life (QOL) as patients' self-reported outcome. *Radiother Oncol* 2013, 106:175–180.
  57. Hauswald H, Rieken S, Ecker S, **Kessel KA**, Herfarth K, Debus J, Combs SE: First experiences in treatment of low-grade glioma grade I and II with proton therapy. *Radiat Oncol* 2012, 7:189.
  58. **Kessel KA**, Habermehl D, Bohn C, Jäger A, Floca RO, Zhang L, Bougatf N, Bendl R, Debus J, Combs SE: [Database supported electronic retrospective analyses in radiation oncology: establishing a workflow using the example of pancreatic cancer]. *Strahlenther Onkol* 2012, 188:1119–1124.
  59. Combs SE, **Kessel KA**, Herfarth K, Jensen A, Oertel S, Blattmann C, Ecker S, Hoess A, Martin E, Witt O, Jäkel O, Kulozik AE, Debus J: Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data. *Radiat Oncol* 2012, 7:170.
  60. **Kessel KA**, Bougatf N, Bohn C, Habermehl D, Oetzel D, Bendl R, Engelmann U, Orecchia R, Fossati P, Pötter

- R, Dosanjh M, Debus J, Combs SE: Connection of European particle therapy centers and generation of a common particle database system within the European ULICE-framework. *Radiat Oncol* 2012, 7:115.
61. Habermehl D, **Kessel KA**, Welzel T, Hof H, Abdollahi A, Bergmann F, Rieken S, Weitz J, Werner J, Schirmacher P, Büchler MW, Debus J, Combs SE: Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. *Radiat Oncol* 2012, 7:28.

### Übersichtsarbeiten, Pubmed listed

1. **Kessel KA**, Combs SE: Digital biomarkers: Importance of patient stratification for re-irradiation of glioma patients - Review of latest developments regarding scoring assessment. *Phys Med* 2019, 67:20-26.
2. Asadpour R, Meng Z, **Kessel KA**, Combs SE. Use of acupuncture to alleviate side effects in radiation oncology: Current evidence and future directions. *Advances in Radiation* 2016; 1: 344-50.
3. **Kessel KA**, Combs SE: Review of developments in electronic, clinical data collection and documentation systems over the last decade – Are we ready for Big Data in routine health care? *Front Oncol.* 2016;6:75–5.

### Book chapters

1. Bougatf N, **Kessel KA**, Bohn C, Oetzel D, Combs SE, Bendl R, Debus J, Engelmann U: Webbasierte Studiendokumentation in der Partikeltherapie mit der CHILI/Telemedizinakte. In *e-Health 2012 Informationstechnologien und Telematik im Gesundheitswesen*. Edited by Duesberg F. Solingen: Medical Future; 2011:205–215.